The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Robert Gordon et al.|Nature Medicine|2021Cited by 599
Criteria for Defining Stages of Cardiogenic Shock SeverityNavin K. Kapur, Daniel Burkhoff, Manreet Kanwar et al.|Journal of the American College of Cardiology|2022Cited by 283
Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic ShockJaime Hernández-Montfort, Navin K. Kapur, Manreet Kanwar et al.|JACC Heart Failure|2022Cited by 88
Impact of Female Sex on Cardiogenic Shock OutcomesVan‐Khue Ton, Navin K. Kapur, Manreet Kanwar et al.|JACC Heart Failure|2023Cited by 49
Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methodsE. Kransdorf, Josef Stehlik, Natasha A. Loghmanpour et al.|Clinical Transplantation|2017Cited by 18